MedTrace Logo

Enoxaparin in the Prevention of Placental Insufficiency in Pregnant Women

NCT03528967 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2020-07-02

No results posted yet for this study

Summary

Assessment of the effectiveness of Enoxaparin, at a preventive dose, combined with Aspirin treatment versus Aspirin only treatment in reducing placental insufficiency in pregnant women.

Conditions

  • Placental Insufficiency
  • Enoxaparin

Interventions

DRUG

Enoxaparin 40 mg / 0.4 mL Prefilled Syringe

DRUG

Aspirin 100 mg Oral Tablet, Enteric Coated

Sponsors & Collaborators

  • Les Laboratoires des Médicaments Stériles

    lead INDUSTRY

Principal Investigators

  • Dalenda Chelly, OB/GYN · Wassila Bourguiba Hospital Tunis

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-23
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • Tunisia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03528967 on ClinicalTrials.gov